ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030 ambitious vision to deliver 20 innovative biomedicines by the end of the decade
Marseille, France, August 29, 2024, 11 am CET – ImCheck Therapeutics announced today that it has received EUR 20.18 million in non-dilutive funding as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government.
The funding will support the development of the company’s most advanced drug candidate, ICT01, a γ9δ2 T cell-activating monoclonal antibody, currently in a Phase I/IIa clinical trial program in various solid cancer and hematologic malignancy indications. The funding also supports ImCheck’s ICT41 pathogen-agnostic infectious disease candidate, which is moving toward clinical development.
“We are honored to be supported by the France 2030 innovation plan. It is a tribute to theprogress we have achieved in the clinic and the overall potential of our novel immunotherapeutic programs. Our approach is both unique and polyvalent, enabling us to address solid tumors, hematologic malignancies and infectious diseases. This recognition from the French government and Bpifrance represents their confidence in our first-in-class therapies, which have the potential to significantly improve patients’ lives,” commented Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics. “We look forward to providing updates from the ICT01 clinical development program as well as other corporate advances later this year.”
Rosalie Maurisse, Head of Healthcare - Innovation division at Bpifrance, added, “Under France 2030, Bpifrance supports French biotech companies that are leading drug development innovation to drive groundbreaking medical advancements. ImCheck’s pipeline programs are highly differentiated and we congratulate the company on this award and the funding to support the acceleration of two of the company’s drug candidates, fully in line with the French Government's healthcare priorities.”
ImCheck has been selected for the French Tech 120 program for the fifth consecutive year, as well as a laureate of the French Tech 2030 program in 2024, recognizing the company as one of the top start-ups/scale-ups contributing to France’s international influence and one of the few organizations developing innovative therapies.These awards, in addition to significant funding from a broad syndicate of leading international life science investors, have enabled the company to progress its broad pipeline through preclinical research and clinical development.